Effective Nutritional Support for Migraine Sufferers*
The power of nutrients is often overlooked when considering effective solutions for migraine sufferers.* Original patented triple-action formula that has been recommended by neurologists, specialists, and healthcare practitioners everywhere for over two decades.
Non-prescription and drug free
Effective for long-term, daily use by ages 13 to throughout adult life
Researched and developed by Akeso Health Sciences Chief Scientific Officer, Curt Hendrix, a nutritional scientist who holds advanced degrees in chemistry and clinical nutrition and has dedicated his life to providing innovative natural medicines
Manufactured in an established GMP facility; third party quality testing
NObutterbur, wheat, gluten, salt, soy, milk or dairy, nuts, corn, caffeine, or artificial flavorings or preservatives; non-GMO and vegan
MigreLief®IS A TRUSTED FORMULA THAT MAKES A DIFFERENCE
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
MigreLief® IS A TRUSTED FORMULA THAT MAKES A DIFFERENCE
Akeso's MigreLief® line of products has successfully been used by hundreds of thousands of customers worldwide for more than 2 decades.
MigreLief® - Original Patented Formula with Puracol®
60 Caplets / 2 per day / 1-month supply
Amount per 2 Tablets
Riboflavin (Vitamin B-2)
Magnesium (as citrate and oxide)
Puracol® Feverfew** (Tanacetum parthenium)
*No Daily Value established
**Puracol® Feverfew is a proprietary combination of whole leaf feverfew that is high in naturally occurring phytochemicals and a special feverfew extract. Feverfew is shown to inhibit histamine release and platelet aggregation leading to vasoconstriction*
Magnesium—two clinically known beneficial forms of magnesium in daily amounts critical to controlling the inhibition of vasospasm and platelet aggregation in support of cerebral vascular tone*
Riboflavin (vitamin B-2)—although necessary for human health, riboflavin is not produced by the body and, therefore, must come from our food or dietary supplementation; high doses of highly absorbable Riboflavin have been proven in clinical studies to reduce the number of neurological discomforts experienced each month and to improve mitochondrial energy deficiencies*
The MigreLief Nutritional Regimen
Choose one of our MigreLief® daily formulas:
MigreLief “Original” – Effective for adults and teens, ages 12 and older
MigreLief+M – For women experiencing hormonal/menstrual related neurologic discomfort
Take 2 per day, every day. Although most see benefits within a few days, these products are designed to provide full benefits within a 90-day build-up period. Thereafter, continue daily use.
And/or chooseMigreLief-NOW for fast-acting, as-needed neurological comfort. Safe and effective for both adults and children age 2 or older. MigreLief-NOW may be combined with any of the other daily MigreLief formulas.
Caution: Not for use during pregnancy, during lactation or by children under 2 years of age.
Riboflavin (Vitamin B-2) can cause urine to become bright yellow. This is normal and harmless.
Although rare, some individuals experience transient (short term) diarrhea when taking magnesium.
Like most dietary supplements, use of MigreLief should be discontinued one week before any surgery.
Brown D, Gaby A, Reichert R. Clinical Applications of Natural Medicine–Migraine. NPRC Condition-Specific Monograph Series, 1997.
Lawrence Review of Natural Products, September 1994.
Awang DVC. Herbal Medicine, Feverfew. Canadian Pharm J 1989; 122:266-70.
Heptinstall S, Awang DVC, Dawson BA, et al. Parthenolide Content and Bioactivity of Feverfew (Tanacetum parthenium). Estimation of Commercial and Authenticated Feverfew Products. J Pharm Pharmacol 1992; 44:391-5.
Pugh WJ, Sambo K. Prostaglandin Synthetase Inhibitors in Feverfew. J Phrm Pharmacol 1988; 40-743-5
Heptinstall S, White A, Williamson L, Mitchell JRA. Extracts of Feverfew Inhibit Granule Secretion in Blood Platelets and Polymophonuclear Leukocytes. Lancet 1985; i:1071-4.
Makheja AN, Bailey JM. A Platelet Phospholipase Inhibitor from the Medicinal Herb Feverfew (Tanacetum parthenium). Prostagland Leukotrienes Med 1982;8:653-60.
Sumner H, Salan U, Knight DW, Hoult JRS. Inhibition of 5-Lipoxygenase and Cyclo-oxygenase in Leukocytes by Feverfew. Biochem Pharmacol 1992;43:2313-20.
Johnson ES, Kadam NP, Hylands DM, Hylands PF. Efficacy of Feverfew As prophylactic Treatment of Migraine. British Med J 1985; 291:569-73.
Murphy JJ. Heptinstall S, Mitchell JRA. Randomized Double-Blind Placebo-Controlled Trial of Feverfew in Migraine Prevention. Lancet 1988; ii:189-92.
Altura BM. Calcium Antagonist Properties of Magnesium: Implications for Anti-migraine Actions. Magnesium 1985; 4:169-75.
Ramadan NM, Halvorson H, Vande-Linde A, et al. Low Brain Magnesium in Migraine. Headache 1989; 29:590-93.
Weaver K. Magnesium and Migraine. Headache 1990; 30:168.
Faccinetti F, Sances G, Borella P, et al. Magnesium Prophylaxis of Menstrual Migraine: Effects on Intra-cellular Magnesium. Headache 1991; 31:298-304.
Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of Migraine with Oral Magnesium: Results from a Prospective, Multi-Center, Placebo-Controlled and Double-Blind Randomized Study. Cephalalgia 1996; 16:257-63.
Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the Prophylaxis of Migraine Cephalalgia 1996;16;436-40
Schoenen J, Lenaerts M, Bastings E. High-dose Riboflavin as a Prophylactic Treatment of Migraine: Results of an Open Pilot Study. Cephalalgia 1994l14:328-9
Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomised controlled trial. Neurology 1998; 50: 46670.
Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhaupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol. 2004 Jul;11(7):475-7.
Maria Condò, Annio Posar, Annalisa Arbizzani and Antonia Parmeggiani Riboflavin prophylaxis in pediatric and adolescent migraine. The Journal of Headache and Pain: Volume 10, Number 5 / October, 2009.